Sponsored - Innovation Theatre
Transforming OA Care: Can Orthobiological interventions postpone surgery in younger patients?
How can we address the large treatment gap in OA with the evidence available today? Osteoarthritis (OA) is a complex disease with no current disease-modifying treatments. However, new research is uncovering molecular changes in early-stage OA, guiding better intervention choices. While early OA can often be managed with weight loss and exercise, and severe OA with joint arthroplasty, there remains a treatment gap for moderate OA, especially in younger patients.
This session will delve into the current challenges and gaps in OA treatment, from both conservative and operative perspectives. We'll examine the impact of these gaps on clinical practice and patient outcomes and explore how emerging technologies might bridge them. With the NHS facing a growing waitlist for joint arthroplasty, we'll discuss how to best utilize existing treatments to manage this crisis.
Associate Professor Jane Fitzpatrick is a renowned Specialist in Sport and Exercise Medicine, serving as the Medical Director and Commercial Leader for Southeast Asia and the Pacific (SE APAC) at Bioventus. With a strong background in sports medicine, she brings a wealth of clinical expertise and strategic leadership to her role. Her work focuses on advancing innovative solutions in orthopaedics and sports medicine across the region, making significant contributions to both patient care and commercial success.
Dr. Peter Shaw serves as the Senior Director of Medical Education at Bioventus, where he is responsible for leading the company’s global medical education initiatives. With a strong background in medicine and a passion for education, Dr. Shaw plays a key role in developing and disseminating knowledge that supports the use of advanced orthobiologic treatments. His work ensures that healthcare professionals worldwide are equipped with the latest insights and best practices in orthopaedics, ultimately improving patient care.
